STAMFORD, Conn., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA) today announced it will focus its resources on the oral difelikefalin Phase 2/3 clinical program in notalgia ...
STAMFORD, Conn., March 07, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of ...
– Oral difelikefalin as adjunct to topical corticosteroids (TCS) did not demonstrate meaningful clinical benefit compared to TCS alone; As a result, Cara will discontinue its clinical program in ...
A small biopharmaceutical company based in Stamford announced that it will lay off 50% of its employees as it seeks to reduce operating expenses, while devoting more resources for clinical trials of a ...
Notalgia paresthetica is an unexplored neuropathy, and yet NP is relatively common. The disease is a chronic neuropathic pruritic condition characterized by pruritus of the upper back, often leading ...
Cara's Therapeutics oral difelikefalin as adjunct therapy to TCS did not demonstrate a meaningful clinical benefit compared to TCS alone. Among CARA's 3 late-stage programs, investors perhaps had the ...
H.C. Wainwright analyst Oren Livnat maintained a Buy rating on Cara Therapeutics (CARA – Research Report) today and set a price target of $3.60. Oren Livnat has given his Buy rating due to a ...
Thank you for standing by, and welcome to Cara Therapeutics Fourth Quarter and Full Year 2023 Earnings Conference Call. At this time all participants are in a listen-only mode. After the speaker ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback